Samsonov Myu 1

1. Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression moderate
2. Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
1